Introduction
With an estimated 429 800 new cases and as the cause of 165 100 deaths annually, bladder cancer (BCa) has become one of the most common and lethal cancers worldwide [1, 2] . In men, BCa is the sixth most common and ninth most lethal type of cancer [1] . In China, although the incidence and mortality rates for BCa have slowly decreased in the past decades [1, 3] , its incidence remains especially high among men, with an estimated 80 500 new cases and 32 900 deaths each year [4] [5] [6] . Given its incidence and lethality, BCa continues to be an important health issue worldwide.
Smoking is currently the most well identified risk factor for BCa, increasing an individual's risk of BCa two-to sixfold [7, 8] . Occupational exposure to dyes, paints and other industrial materials are also considered important BCa risk factors, accounting for~10% of all cases [8] . Furthermore, studies have suggested that inherited risk factors are another major component that contribute to BCa risk, with a heritability estimate of 30% [9] . In a Nordic twin study, results suggested that individuals whose monozygotic/ dizygotic twin had BCa were at a 9.9-/5.5-fold increased risk of BCa. Another study reported that patients with a positive family history of BCa were twice as likely to develop BCa than those without such a family history [10] . In addition to family history, heritable genetic variants associated with BCa have been discovered. For example, more than 20 common single nucleotide polymorphisms have been reported in genome-wide association studies [11] . Rare germline genetic variants with high penetrance, however, have not been systematically evaluated. Only sporadic cases have been reported in families with heredity cancer predisposition syndromes, such as Lynch syndrome-related gene mutations and Li Fraumeni Syndrome [12, 13] .
There are currently no universally accepted algorithms for BCa screening and treatment [1] . Regular urine analysis or ultrasonography that are included as part of a routine physical examination in every individual lack sensitivity and effectiveness. Screening high-risk individuals, however, could improve both of these problems. In addition, given the high recurrence/progression rates of BCa it is often difficult to accurately predict prognosis based on current clinical risk assessment tools. Based on results from the European Organization for Research and Treatment of Cancer (EORTC) study,~47% of patients with non-muscle invasive BCa (NMIBC; Tis, Ta or T1) had at least one recurrence after treatment (primarily transurethral resection of bladder tumour) with a median follow-up of 3.9 years, and a disease progression rate of 11% [14] . The risk of recurrence and progression cannot be fully explained by clinical risk factors, such as tumour size, number of tumours or clinical stage [14] . Addressing these clinical issues is challenging, but elucidating the risk factors for disease onset, recurrence and progression could lead to a paradigm change that would significantly improve clinical care.
Recent studies have reported that somatic mutations in DNA repair genes occur frequently in BCa tumours. Specifically, Pietzak et al. [15] found that DNA repair gene alterations were found in~30% of patients with high-grade NMIBC and muscle-invasive bladder cancer (MIBC). Mutations in DNA repair genes were also found to be closely correlated with an improved response to treatments such as platinum-based chemotherapy, PARP inhibitors, BCG or checkpoint inhibitors [15] [16] [17] [18] . Despite promising studies investigating somatic genetic alterations in DNA repair genes in BCa, germline mutation status remains poorly understood; therefore, in the present study, we tested germline DNA repair gene mutations in BCa using a customized targeted sequencing panel. Using cases from our own hospital-based population and a control population derived from public databases, with case-control and case-case study designs, we were able to investigate the effect of germline pathogenic/likely pathogenic mutations in DNA repair genes on BCa aggressiveness.
Materials and Methods

Study Population
The study was approved by the institutional review board at Huashan Hospital. Written informed consent was obtained from all participants. A total of 98 patients with bladder urothelial carcinoma who received surgical treatment at Huashan Hospital, Fudan University, Shanghai China from 2011 to 2015 were included in this study. Of the 98 patients, 60 had a diagnosis of NMIBC (Ta and T1 NMIBC), and the remaining 38 patients were diagnosed with MIBC. The selected patients had available germline DNA samples, pathological diagnosis information and follow-up information. None of the patients had a history of other types of cancers or related cancer predisposition syndrome, to the best of our knowledge, according to the medical records. Patients were excluded if information regarding their diagnosis, recurrence, or progression was missing. Demographic and clinical information for each patient was obtained from the medical records. Unfavourable disease outcomes during follow-up were defined as an initial diagnosis of NMIBC with early recurrence (after <12 months), multiple recurrences, or progression to MIBC. All patients included in the study had available blood specimens, and DNA extraction was performed at the Fudan Institute of Urology, Huashan Hospital.
Sequencing, Bioinformatics and Statistical Analysis
A customized next-generation sequencing panel that targeted 222 cancer-related genes was used to sequence the germline DNA samples, including 54 DNA repair genes and 168 cancerrelated genes in other biological pathways. The pipelines used for sequencing and bioinformatics analysis were described in our previous study [19] . Notably, more stringent criteria were used to identify the pathogenicity of variants in addition to the American College of Medical Genetics and Genomics criteria [20, 21] . Briefly, pathogenic and likely pathogenic mutations were defined as: (i) all protein-truncating mutations, unless their allele frequency was ≥1% in the East-Asian population based on information in the Exome Aggregation Consortium database (ExAC) or the Genome Aggregation Database (gnomAD); (ii) any non-synonymous mutations with allele frequency <1% in the East-Asian population and categorized as pathogenic/likely pathogenic for cancer-related diseases in the ClinVar database; (iii) any non-frameshift mutations involving more than three amino acids.
Frequencies of pathogenic/likely pathogenic mutations in DNA repair genes in the East-Asian population were obtained from ExAC and GnomAD. Comparisons of pathogenic/likely pathogenic mutation frequencies were evaluated using Fisher's exact test. A type I error of 0.05 (two-sided) was used to define statistical significance.
Results
The demographic and clinical information from the study cohort is shown (Table 1 ). A total of 98 patients diagnosed with bladder urothelial carcinoma were included, of whom 60 were diagnosed with NMIBC (T stage: Ta, T1) and 38 were diagnosed with MIBC (T2 or higher). Eleven out of 38 patients with MIBC were initially diagnosed as having NMIBC and progressed to MIBC during the follow-up. The median ages at diagnosis were 60.5, 71.0 and 67.0 years in patients with Ta, T1 and ≥T2 cancers, respectively. The male to female ratios in patients with different T stages were approximately 4:1, similar to epidemiology data from the general population [2] . Of 71 patients who were initially diagnosed with NMIBC, 20 (28.17%) had disease recurrence and 11 (15.49%) progressed to MIBC. In addition, 17 patients (17.3%) had unfavourable disease outcomes.
Germline pathogenic and likely pathogenic mutations were observed in eight DNA repair genes, including CHEK2, ERCC5, GEN1, MLH1, PALB2, RAD50, RAD51B and RECQL4. The positions of the mutations are shown in Fig. 1 . Detailed information about the mutations in each study participant is given in Table S1 . Briefly, 10 mutation carriers were observed in 98 patients; the carrier rate was 10.2%.
To evaluate the association between DNA repair gene mutations and risk of BCa, we compared the carrier frequencies in the present study population to those in the general East-Asian population (Table 2) . Pathogenic/likely pathogenic mutations of ERCC5 were significantly associated with BCa when compared with carrier rates obtained from ExAC and GnomAD (All P < 0.05). Several genes did not reach statistical significance because of the relatively small sample size; however, they are worth further investigation. For example, the carrier rates of mutations in GEN1, MLH1, PALB2, RAD50 and RECQL4 were 4-to 15-fold higher in the patients with BCa than in the general population. We further evaluated the association between pathogenic/ likely pathogenic mutations in DNA repair genes and disease aggressiveness based on various phenotypes (Tables 3 and 4 ). Within the subset of patients with MIBC, the frequency of mutations was 15.8%,~2.4-fold higher than in patients with NMIBC (6.67%; P = 0.18). In patients who were initially diagnosed with NMIBC, mutation carriers were approximately twice as likely to experience disease recurrence than non-carriers (50.0% vs 25.4%; P = 0.21), and~5-fold more likely to have progression to MIBIC (50.0% vs 11.11%; P = 0.017). The mutation frequency in patients with earlyonset disease (at age <45 years) was~3-fold higher than in patients with disease onset ≥45 years (28.57% vs 8.79%; P = 0.15). Among the 17 patients who had unfavourable clinical outcomes, five (29.41%) carried deleterious germline mutations in DNA repair genes. The mutation frequency was significantly higher than in those who did not have unfavourable outcomes (5/81 patients, 6.17%; P = 0.013).
Smoking history information was only available in 80 patients. Nine of these reported a heavy smoking history (having a smoking history of ≥5 years with ≥10 cigarettes daily). Four out of 20 patients with MIBC reported a heavy smoking history, while five of 60 patients with NMIBC (8.33%) reported a heavy smoking history (P = 0.22; Table 1 ). In mutation carriers, only one reported a heavy smoking history (Patient ID 38, Table S1 ). In the patients without a smoking history, six carriers were observed, and two of them had unfavourable outcomes (33.33%), while five of 65 noncarriers (7.69%) had unfavourable outcomes (>4-fold higher; P = 0.09). Because of the relatively small sample size, we were unable to fully evaluate the interaction between smoking and mutation status.
We also evaluated the association between DNA repair gene mutations and drug response to cisplatin-based chemotherapy. Because most of the patients had received adjuvant chemotherapy in other local hospitals, only six patients with MIBC with medical records of adjuvant chemotherapy could be found. Interestingly, two patients who carried PALB2 and RAD50 germline mutations died in the 18th and 24th month after surgery, respectively, while three other non-carriers who received gemcitabine plus cisplatin chemotherapy have survived for a longer period (Fig. S1 ). Table 2 Comparisons of DNA repair gene carrier rates between cases from the present study and controls from public databases.
Genes Present study population (case) Public database (control)
Huashan Hospital (n = 98) n (%) 
Discussion
To gain a better understanding of germline mutations in DNA repair genes in BCa, we conducted the present study of 54 DNA repair genes in 98 patients with BCa. Despite the relatively small sample size, several important results were notable. First, we detected 10 carriers of eight mutated genes in 98 patients with BCa (10.2%), which was higher than the average population carrier rate (~2.9% based on public databases). Second, we found that germline pathogenic/likely pathogenic mutations in DNA repair genes were significantly associated with disease progression from NMIBC to MIBC. Finally, mutation status was significantly associated with negative prognostic features. The carrier frequency in patients with unfavourable outcomes (early recurrence or progression to MIBC) was~4.8-fold higher than patients with relatively favourable prognoses.
Except for genome-wide association studies and other association studies investigating common genetic variants, very few studies have been reported evaluating the correlation between germline, rare deleterious mutations and BCa, especially for DNA repair genes. Several studies reported the association between single nucleotide polymorphisms in ERCC5 and BCa, but with contradictory results [22, 23] . In the present study, we found that carrier rates of pathogenic/likely pathogenic ERCC5 mutations might be associated with BCa; but, because of the relatively small sample size, our results should be considered preliminary until further prospective studies are conducted. In addition to ERCC5 mutations, we also observed that the frequencies of mutations in GEN1, MLH1, PALB2, RAD50, RAD51B and RECQL4 were 4-to 15-fold higher in patients with BCa than in the general population. The association between BCa and pathogenic mutations in these DNA repair genes has rarely been reported and is therefore worth further investigation. Another notable finding is that we did not observe any BRCA1/2 carriers in the study. In a study investigating germline mutation status of DNA repair genes in 101 patients with urothelial carcinoma (including renal pelvis, ureter and bladder) by Carlo et al. [24] , three BRCA1 and 2 BRCA2 carriers were reported; however, it is unclear whether the mutations in BRCA1/2 were associated with renal pelvis cancer, cancer of the ureter or BCa because of a lack of detailed information in this conference abstract. As very few results have been reported from other studies [25] [26] [27] , we propose that patients carrying or with a family history of BRCA1/2 do not necessarily have elevated risk for developing BCa, although much larger studies are necessary to evaluate this possibility.
It has previously been suggested that mutations within DNA repair genes correlate with responsiveness to chemotherapy. Based on a study by Plimack et al. [28] , not all the DNA repair genes mutations were associated with better response to cisplatin-based chemotherapy. In this comprehensive study, they suggested that mutations in ATM, RB1 and FANCC may correlate with better response to cisplatin-based chemotherapy [28] . In the present study, however, because of the small sample size, we failed to observe similar results.
Our findings have important clinical implications. Genetic testing of DNA repair genes may help predict disease aggressiveness and prognoses for patients who have already been diagnosed with BCa. Our data showed that 50.0% of the DNA repair gene mutation carriers had the unfavourable disease outcomes of short-term recurrence and/or progression, compared with 13.64% of non-carriers. Based on these results, patients carrying deleterious mutations in DNA repair genes should receive personalized postsurgical therapies such as PARP inhibitors. Prospective clinical trials are needed to validate the utility of our results.
Several limitations of this study should be mentioned, including the relatively small sample size (only 98 patients with BCa). Further studies with larger sample sizes are necessary to validate our results. Secondly, family history information was not available from the patients. Finally, we used a general East-Asian population from a public database as a control group instead of using a Chinese population; however, populations in the East Asia region (China, Japan, Korea, etc.) are known to have the same origin and a similar genetic background; we believe, therefore, that genetic information obtained from a general East Asian population was an appropriate control. Future studies should nevertheless recruit controls prospectively from the same institutions.
In conclusion, pathogenic and likely pathogenic mutations in DNA repair genes were associated with increasing risk of progression from NMIBC to MIBC and with an unfavourable prognosis.
